FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome
The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.
Related Articles
Home exercise plus protein supplementation helps patients with frailty undergoing TAVR
ATLANTA — A home-based exercise intervention with protein supplementation improved physical performance at 12 weeks for older patients with frailty who underwent transcatheter aortic valve…
Climbing stairs reduces risk for all-cause, cardiovascular death
In a meta-analysis of studies covering more than 400,000 people, climbing stairs was associated with reduced risk for all-cause mortality and death from heart disease.“If…
Asthma risks on the rise due to climate change
Climate change has resulted in higher pollution levels, more wildfires and warmer temperatures, all of which come together and increase the risk for asthma, according…
Most US adults estimated to have subclinical cardiovascular-kidney-metabolic syndrome
More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome, according to a research letter published in the Journal of…
EPA finalizes emission limits for power plants
The U.S. Environmental Protection Agency has finalized standards lowering mercury and toxic metal emissions, as well as carbon pollution from power plants, according to a…
Asthma risks on the rise due to climate change
Climate change has resulted in higher pollution levels, more wildfires and warmer temperatures, all of which come together and increase the risk for asthma, according…
VIDEO: How the gut microbiome can influence obesity treatment
DENVER — Prior studies have shown that many diseases are tied to the gut microbiome, including metabolic disorders such as obesity, according to Sahil Khanna,…
VIDEO: Half of patients with obesity face nutritional deficiencies
DENVER — It is important for clinicians to check for nutritional deficiencies in patients with obesity, a speaker at the Obesity Medicine Association conference noted.Patients…
HCC screening linked to reduced mortality but remains ‘underused in clinical practice’
Hepatocellular carcinoma screening in at-risk patients was linked to reduced mortality after accounting for lead-time and length-time biases, as well as improved early tumor detection…
Nearly half of patients with giant cell arteritis achieve remission with upadacitinib
Nearly half of patients with giant cell arteritis who received upadacitinib while tapering steroids achieved remission from weeks 12 through 52 in a phase 3…
